Rx-360 Summary of Michigan State University Center for Anti-Counterfeiting and Product Protection Risk of Counterfeiting Report
Michigan State University Center for Anti-Counterfeiting and Product Protection published a report titled “Assessing the Risks of Counterfeiting and Illicit Diversion for Health Care Products” in November 2013.
This report addresses the multiple risks of counterfeit and diverted health care products including adulteration with dangerous chemicals, and diluted/sub-potent APIs and dosage form. The adulterations can happen either through inadvertent GMP failures or through intentional economic motivated adulteration. Further complicating this issue is the fact that legitimate product that is not maintained under appropriate environmental conditions or handled incorrectly, as may happen with diverted health care products, may lose potency and become ineffective or even harmful.
The paper identifies potential questions that should be considered in determining the potential risk to patients from a counterfeit or diversion incident (see pages 3–8). Answers to these questions identify areas of concern that should be considered to mitigate the identified risks. Such activities are meant to be ongoing and reviewed frequently as the landscape for these type of illegal activities changes rapidly.
To view or download the summary, click here
To view or download the report, click here
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance